Hairy cell leukemia

Ronan T Swords, Francis Giles

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by pancytopenia and variable infiltration of the reticuloendothelial system with "hairy" lymphocytes. HCL is more common in men than women and has a median age of diagnosis of 52 yr. Typically, patients with HCL respond well to purine analog-based therapy. The purpose of this review will be to establish the current status of HCL with respect to its pathophysiology, diagnosis, management, and future directions.

Original languageEnglish
Pages (from-to)7-15
Number of pages9
JournalMedical Oncology
Volume24
Issue number1
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Hairy Cell Leukemia
Pancytopenia
Mononuclear Phagocyte System
Lymphoproliferative Disorders
B-Lymphocytes
Lymphocytes
Therapeutics

Keywords

  • Hairy cell leukemia
  • Pathophysiology
  • Purine analogs
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Swords, R. T., & Giles, F. (2007). Hairy cell leukemia. Medical Oncology, 24(1), 7-15. https://doi.org/10.1007/BF02685898

Hairy cell leukemia. / Swords, Ronan T; Giles, Francis.

In: Medical Oncology, Vol. 24, No. 1, 01.06.2007, p. 7-15.

Research output: Contribution to journalArticle

Swords, RT & Giles, F 2007, 'Hairy cell leukemia', Medical Oncology, vol. 24, no. 1, pp. 7-15. https://doi.org/10.1007/BF02685898
Swords RT, Giles F. Hairy cell leukemia. Medical Oncology. 2007 Jun 1;24(1):7-15. https://doi.org/10.1007/BF02685898
Swords, Ronan T ; Giles, Francis. / Hairy cell leukemia. In: Medical Oncology. 2007 ; Vol. 24, No. 1. pp. 7-15.
@article{78a63d67883a4047b99c4e659e13b52a,
title = "Hairy cell leukemia",
abstract = "Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by pancytopenia and variable infiltration of the reticuloendothelial system with {"}hairy{"} lymphocytes. HCL is more common in men than women and has a median age of diagnosis of 52 yr. Typically, patients with HCL respond well to purine analog-based therapy. The purpose of this review will be to establish the current status of HCL with respect to its pathophysiology, diagnosis, management, and future directions.",
keywords = "Hairy cell leukemia, Pathophysiology, Purine analogs, Treatment",
author = "Swords, {Ronan T} and Francis Giles",
year = "2007",
month = "6",
day = "1",
doi = "10.1007/BF02685898",
language = "English",
volume = "24",
pages = "7--15",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Hairy cell leukemia

AU - Swords, Ronan T

AU - Giles, Francis

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by pancytopenia and variable infiltration of the reticuloendothelial system with "hairy" lymphocytes. HCL is more common in men than women and has a median age of diagnosis of 52 yr. Typically, patients with HCL respond well to purine analog-based therapy. The purpose of this review will be to establish the current status of HCL with respect to its pathophysiology, diagnosis, management, and future directions.

AB - Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by pancytopenia and variable infiltration of the reticuloendothelial system with "hairy" lymphocytes. HCL is more common in men than women and has a median age of diagnosis of 52 yr. Typically, patients with HCL respond well to purine analog-based therapy. The purpose of this review will be to establish the current status of HCL with respect to its pathophysiology, diagnosis, management, and future directions.

KW - Hairy cell leukemia

KW - Pathophysiology

KW - Purine analogs

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34548809050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548809050&partnerID=8YFLogxK

U2 - 10.1007/BF02685898

DO - 10.1007/BF02685898

M3 - Article

C2 - 17673807

AN - SCOPUS:34548809050

VL - 24

SP - 7

EP - 15

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

ER -